Severe Inflammatory Acne Vulgaris
Highly investigational use for severe nodulocystic acne refractory to isotretinoin; small Ayurvedic studies only, none in refractory disease, and scarring risk concerns.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for acne. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for nodulocystic acne is investigational and considered exploratory.
- What evidence exists?
- Tier C (investigational). Only small studies and case reports were found, mostly from Ayurvedic centers: a 14-patient single-group study, a 40-patient randomized comparison of leech application plus a herbal paste versus the paste alone, and case reports. In the two studies the abstracts do not describe severe nodulocystic or isotretinoin-refractory acne, and neither compared leeches with isotretinoin. Evidence-based therapy for severe inflammatory nodulocystic acne is isotretinoin (95 percent response rate), with adjunctive doxycycline, hormonal therapy (combined oral contraceptives, spironolactone in women), and topical retinoids. AAD guidelines establish isotretinoin as standard. The risk-benefit ratio of leech therapy is unfavorable in most patients given scarring risk.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Significant post-inflammatory hyperpigmentation, especially in Fitzpatrick IV-VI skin
- Permanent scarring or new acne-scar formation at bite sites
- Worsening of cystic acne if leech placed on cyst centers
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Drug-leech interaction unknown if on isotretinoin (bleeding risk theoretical)
- Delay of evidence-based isotretinoin or hormonal therapy
- Who should not consider this
- Patients currently on isotretinoin therapy (bleeding-risk interaction unknown)
- Patients with prior keloid or hypertrophic scarring tendency
- Patients with acne fulminans (systemic corticosteroid emergency)
- Patients with darker Fitzpatrick skin types at high PIH risk
- Patients on anticoagulants or with anemia
- Patients who have not been offered isotretinoin by a dermatologist
- What to ask your clinician
- Have I tried isotretinoin, or do I have a contraindication?
- What is the realistic risk that bite sites will scar or hyperpigment given my skin type?
- What evidence supports leech therapy for severe acne specifically?
- Will placement be on intact skin adjacent to nodules, never on the cyst itself?
- Are leeches from an FDA-registered supplier and used only once?
- What is the Aeromonas-prevention plan?
- What is the cost and is it covered by insurance? (typically not covered)
- When to seek urgent care
- Sudden rapid worsening with fever, severe joint pain, and ulcerating nodules (acne fulminans — emergency)
- Spreading redness, warmth, pus, or red streaks (cellulitis or abscess)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Severe bleeding combined with isotretinoin use (rare but possible)
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
What this does NOT mean
- This is NOT FDA-cleared for acne vulgaris.
- Small studies and case reports do NOT establish efficacy versus isotretinoin, the gold-standard treatment; none compared leeches with it.
- It does NOT mean leech therapy is safe in patients prone to scarring or hyperpigmentation — risks may outweigh benefits.
- It does NOT mean cystic acne should be treated by anyone other than a dermatologist with full pharmacologic options.
- It does NOT substitute for isotretinoin, hormonal therapy, or topical retinoids in evidence-based regimens.
Safety cross-references
Clinical Profile
- Category
- Dermatological
- ICD-10
- L70.0, L70.1, L70.8, L70.9
- Safety tier
- High
Evidence Summary
Clinical evidence is limited to small Ayurvedic studies in acne vulgaris of unspecified severity, none in isotretinoin-refractory nodulocystic acne: a single-group study of 14 patients given leech sittings (Gupta 2021), a randomized comparison of 40 patients receiving leech application plus a herbal paste versus the paste alone (Bhadauria 2025), and case reports. Neither study compared leeches with isotretinoin or another standard acne therapy. Severe inflammatory (nodulocystic) acne vulgaris is conventionally treated with isotretinoin (high response rate) and adjunctive antibiotics or hormonal therapy. Leech application also carries a significant risk of post-leech-site hyperpigmentation and scarring that could worsen cosmetic outcomes. Evidence is grade D and the risk-benefit ratio is unfavorable for most patients. Isotretinoin completion (with appropriate monitoring) remains the standard of care.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active isotretinoin therapy (drug-leech interaction unknown; bleeding risk)
- Prior keloid or hypertrophic scarring tendency
- Acne fulminans (systemic corticosteroid emergent)
- Patients with darker Fitzpatrick skin types at high PIH risk
Related Conditions
Rosacea (Erythematotelangiectatic)
Investigational use for erythematotelangiectatic rosacea; no clinical study of leech therapy was identified.
Hidradenitis Suppurativa (Hurley Stage I-II)
Not recommended: the only published report of leech therapy in hidradenitis suppurativa describes a harmful outcome.
Livedo Reticularis
Investigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; no study in this condition was identified, only small series in venous ulcer and varicose disease.